Abstract
Background Although perioperative fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) is the standard neoadjuvant regimen for resectable gastric and gastro-oesophageal junction adenocarcinoma, evidence describing treatment delivery in routine clinical practice remains limited, particularly regarding relative dose intensity (RDI) and treatment completion.
Objectives To evaluate real-world delivery of preoperative FLOT chemotherapy, including treatment completion, progression to surgery, RDI, toxicity and exploratory changes in estimated lean body mass (LBM).
Methods A retrospective single-centre service evaluation included consecutive patients receiving neoadjuvant FLOT during 2024. Outcomes included treatment completion, surgery, RDI, toxicity, pathological response and estimated LBM. Descriptive statistics were used.
Results Twelve patients were included (median age 68.6 years; 91.7% male). Eleven (91.6%) completed all four preoperative cycles and proceeded to surgery. Mean RDI was 76.7%. Pre-emptive dose capping was the predominant dose modification strategy, with only one reactive dose reduction. Two grade 3 adverse events occurred. Major pathological response (Mandard grade 1–2) was observed in 2/12 patients (16.7%). Mean estimated LBM declined from 54.3 to 53.4 kg. Greater LBM loss appeared to coincide with poorer clinical outcomes.
Conclusions High treatment completion and progression to surgery were achieved despite reduced RDI. These findings support prospective evaluation of strategies to optimise chemotherapy delivery while maintaining tolerability in routine clinical practice.
What is already known on this topic?Perioperative FLOT is standard treatment for resectable gastric and gastro-oesophageal junction adenocarcinoma, but toxicity frequently necessitates dose modification. Real-world data on relative dose intensity and treatment completion remain limited.
What this study adds?In this single-centre cohort, 91.6% of patients completed all four planned preoperative FLOT cycles and proceeded to surgery despite a mean relative dose intensity of 76.7%. Pre-emptive dose capping was the predominant dose-modification strategy.
How this study might affect research, practice or policy?Routine monitoring of relative dose intensity alongside treatment completion may provide a useful measure of chemotherapy delivery. Larger studies should evaluate whether individualised dose optimisation can maintain treatment continuity while balancing toxicity and dose intensity.
Competing Interest Statement
The authors have declared no competing interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No ethics approval was required, the service evaluation was registred with York and Scarborough clinical governance team and the dataset used for fully anonymised, no patient consent was required for this. The evaluation was registered with the hospital clinical governance department (CSCS/ONC/142).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors. These will be shortly uploaded to zenodo (the data file)





